Heather Rees - 15 May 2025 Form 4 Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)

Reporting relationship: Chief Financial Officer
Issuer ticker: ATOS
Reported as of: 15 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 May 2025, 16:05:13 UTC
Prior SEC filing: 01 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Heather Rees

Key filing fact

Heather Rees filed Form 4 for ATOSSA THERAPEUTICS, INC. (ATOS) on 16 May 2025.

Key facts

This page summarizes Heather Rees's Form 4 filing for ATOSSA THERAPEUTICS, INC. (ATOS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 May 2025, 16:05.

Change

Previous filing in this sequence was filed on 01 Jul 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001997454 Primary reporting owner

Rees Heather

Relationship: Chief Financial Officer
Address: C/O ATOSSA THERAPEUTICS, INC.,, 10202 5TH AVENUE NE SUITE 200, SEATTLE
Signature: /s/ Heather Rees
Signature date: 16 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATOS transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +543,785
Change %
Price: $0.000000
Shares after: 543,785
Date: 15 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 543,785
Exercise price: $0.9900
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options shall vest on a quarterly basis over 24 months following May 15, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on May 15, 2025, with an exercise price of $0.99, representing the closing stock price on May 15, 2025.